BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
What happened
On September 23, 2026, the FDA approved lirafugratinib — brand name Lyrfigtu, from Elevar Therapeutics — for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (bile duct cancer) harboring FGFR2 gene fusions or other rearrangements, according to the FDA’s own approval notice. The recommended dose is 70 mg once daily, taken orally.
The approval rests on the REFOCUS trial of 116 previously treated, FGFR-inhibitor-naive patients, where the objective response rate was 46% and the median duration of response was 11.8 months. Key facts:
- FDA used its Real-Time Oncology Review and granted priority review, breakthrough therapy, and orphan drug designations
- Elevar says the drug should be available in the U.S. in the fourth quarter of 2026
- Label warnings include ocular toxicity, hyperphosphatemia, soft tissue mineralization, and embryo-fetal toxicity
Why it matters
This is the third FGFR inhibitor cleared for FGFR2-positive bile duct cancer, after Incyte’s pemigatinib (2020) and Taiho’s futibatinib (2022) — but the first to win a full “approved” label rather than accelerated approval. Lyrfigtu is also the first highly selective FGFR2 inhibitor; its predecessors block FGFR1–4 broadly, which matters because selectivity is the drug’s core differentiation story.
There is a notable business angle too: Elevar is a majority-owned subsidiary of Korea’s HLB, while the molecule itself was created by U.S.-based Relay Therapeutics and out-licensed worldwide to Elevar in December 2024. For investors in Relay (RLAY), this is a real-world validation of its computation-driven discovery platform.
What to watch
Watch the Q4 2026 U.S. launch — pricing and initial uptake will show whether selectivity translates into market share against the two incumbents. Also watch Relay Therapeutics’ commentary on milestone economics and what this approval does for its pipeline credibility.
Related reading: Ultragenyx Wins FDA Approval for First-Ever Sanfilippo Syndrome Type A Treatment | Mirum’s Atebrioz Wins FDA Approval for Ultra-Rare FOP Bone Disorder
Will Lyrfigtu’s FGFR2 selectivity be enough to take meaningful share from the two incumbent FGFR inhibitors?
Sources: FDA, Pharmacy Times
Not financial advice. Auto-posted by the Bull Lounge news desk.Log in to vote
